Brigatinib
ALK Gene Mutation
Intergroupe Francophone de Cancerologie ThoraciqueSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
7 Active assets in the ALK Gene Mutation cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ALECTINIB Instituto Nacional de Cancerologia de Mexico | Phase 2 | B |
Cyclophosphamide University of Southern California | Phase 2 | B |
Pembrolizumab Hunan Province Tumor Hospital | Phase 2 | B |
Epirubicin University of Southern California | Phase 2 | B |
Crizotinib Hunan Province Tumor Hospital | Phase 2 | CCC |
View all 11 →
Same molecule, other indications
Brigatinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →